Lv51
1020 积分 2024-04-17 加入
A Model‐Based Approach to Quantify the Time‐Course of Anti‐Drug Antibodies for Therapeutic Proteins
12秒前
待确认
Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations
1分钟前
待确认
A Challenge for Clinical Pharmacologists: How Can We Measure Scientific Impact of Publications in Drug Development and in Regulatory Decision Making?
2分钟前
待确认
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
4分钟前
待确认
1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies
6天前
已完结
Machine Learning for Prediction of Drug Concentrations: Application and Challenges
10天前
已完结
A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence Assessments
10天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
3个月前
已完结
Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures
3个月前
已完结
Exploratory food effect assessment in patients in early clinical development of oncology drugs
3个月前
已完结
皖公网安备34019202002308
